Doximity (NYSE:DOCS) Raised to Moderate Buy at Royal Bank Of Canada

Doximity (NYSE:DOCS) was upgraded by analysts at Royal Bank Of Canada to a “moderate buy” rating in a research report issued on Thursday,Zacks.com reports.

DOCS has been the topic of a number of other research reports. Barclays raised shares of Doximity to a “strong-buy” rating in a research report on Monday, December 8th. The Goldman Sachs Group raised shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Friday. Wall Street Zen cut Doximity from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Doximity in a report on Wednesday, December 24th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Doximity Trading Up 0.3%

NYSE DOCS opened at $43.85 on Thursday. Doximity has a 52 week low of $43.21 and a 52 week high of $85.21. The company has a market capitalization of $8.26 billion, a price-to-earnings ratio of 34.80, a PEG ratio of 2.03 and a beta of 1.39.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Truist upgraded DOCS from “hold” to “strong-buy,” signaling conviction in near-term upside and product/market momentum that could support a rebound in shares. Truist Upgrade
• Positive Sentiment: Royal Bank of Canada (RBC) moved DOCS to a “moderate buy,” citing a durable growth moat—this bolsters the long-term growth thesis and may attract buyers looking past recent volatility. RBC Coverage
• Positive Sentiment: Goldman Sachs upgraded DOCS from “strong sell” to “hold” — a move that reduces downside risk from a major house, even as Goldman warns of a valuation reset; the change can remove selling pressure tied to the prior very negative rating. Goldman Upgrade
• Neutral Sentiment: Coverage pieces assess DOCS vs. peers and provide a critical review of positioning—useful context for investors but not an immediate catalyst by themselves. Competitor Review
• Neutral Sentiment: Yahoo Finance examines valuation after volatile trading and discusses recent AI product updates; product developments are positive, but valuation and volatility keep the near-term outlook mixed. Valuation & AI Update
• Negative Sentiment: Wall Street Zen lowered DOCS to a “hold,” which could add selling pressure among investors who react to fresh downgrades and heighten short-term caution. Wall Street Zen Downgrade

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.